Ken Griffin
OTLK icon

Ken Griffin’s Outlook Therapeutics OTLK Stock Holding History

Ken Griffin’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.4K Sell
113,700
-7,600
-6% -$3.28K ﹤0.01% 12634
2025
Q4 		$192K Buy
121,300
+104,100
+605% +$166K ﹤0.01% 11078
2025
Q3 		$18.2K Buy
+17,200
New +$29.7K ﹤0.01% 12506
2025
Q2 		– Sell
-39,100
Closed -$47.7K – 14369
2025
Q1 		$47.7K Buy
39,100
+5,700
+17% +$9.99K ﹤0.01% 12363
2024
Q4 		$63.1K Sell
33,400
-41,000
-55% -$169K ﹤0.01% 12122
2024
Q3 		$397K Buy
+74,400
New +$544K ﹤0.01% 8732

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $145M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $995M AUM 22.79% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Ken Griffin's OTLK Position: Q1 2025 in Review

Ken Griffin sold out of Outlook Therapeutics (OTLK) in Q1 2025, closing a stake of 8,692 shares — an estimated $15.2K sold.

Ken Griffin first reported a position in OTLK in Q4 2017 and held it in 13 quarters. The position peaked at $397K in Q1 2021. 63 funds tracked by Wall St. Rank hold OTLK as of Q1 2025.

  • Ken Griffin reported no remaining Outlook Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Ken Griffin sold 8,692 Outlook Therapeutics shares in Q1 2025, an estimated $15.2K.
  • Ken Griffin first reported a position in Outlook Therapeutics in Q4 2017 and held it in 13 quarters.
  • Ken Griffin's Outlook Therapeutics position peaked at $397K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2025.

Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.